Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 7/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096254 | 0.86 | NPC1 (0.46) | LMNAPOLBTP53DRD4DRD2 | |
| SCHEMBL3084210 | 0.82 | ATM (0.44) | LMNATSHRSIGMAR1SLC6A4ALDH1A1 | |
| SCHEMBL3085317 | 0.82 | SIGMAR1 (0.51) | TSHRSIGMAR1DRD4DRD2ALDH1A1 | |
| SCHEMBL3095186 | 0.82 | DRD4 (0.44) | POLBTP53DRD4DRD2ALDH1A1 | |
| SCHEMBL7835140 | 0.76 | ALDH1A1 (0.41) | LMNAPOLBTP53TSHRDRD4 | |
| SCHEMBL3098204 | 0.75 | ALDH1A1 (0.58) | LMNAPOLBTSHRSIGMAR1DRD4 | |
| SCHEMBL29116672 | 0.74 | LMNA (0.57) | LMNAPOLBTP53TSHRSIGMAR1 | |
| SCHEMBL7835294 | 0.73 | ALDH1A1 (0.45) | LMNASIGMAR1DRD4DRD2ADRA1A | |
| SCHEMBL11784819 | 0.72 | HDAC1 (0.61) | LMNAPOLBTSHRSIGMAR1ALDH1A1 | |
| SCHEMBL29483477 | 0.72 | HDAC1 (0.61) | LMNAPOLBTSHRSIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207134-B2 | Fused ring spiroketal derivative and use thereof as anti-diabetic drug | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2048152-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | REN, WNK1, GCKR | LMNA 2203/4885POLB 4613/4885TP53 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.